Verapamil

• Catalog No.: DB00661
• CAS Number: 52-53-9
• M. F.: C27H38N2O4
• M. W.: 454.60162

SYNONYMS

• IUPAC name: 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
• IUPAC Traditional name: verapamil
• Brand Name: Univer; Apo-Verap; Verexamil; Geangin; Berkatens; Cardiagutt; Cardibeltin; Dignover; Isoptimo; Isoptin; Isoptin SR; Securon; Veramex; Arpamyl; Calan; Calan SR; Cordilox; Covera-HS; Dilacoran; Drosteakard; Iproveratril; Novo-Veramil; NU-Verap; Quasar; Vasolan; Veracim; Veraptin; Verelan; Verelan PM
• Synonyms: Verapamil HCl; Verapamilo [INN-Spanish]; Verapamilum [INN-Latin]; Verapamil [Usan:Ban:Inn]

DATABASE IDS

• PubChem CID: 2520
• CAS Number: 52-53-9
• PubChem SID: 46508158

PROPERTIES

• Hydrophobicity(logP): 4.7
• Solubility: 4.47 mg/L

DETAILS

Description (English)

• Drug Groups: approved
• Description: A calcium channel blocker that is a class IV anti-arrhythmia agent. [PubChem]
• Indication: For the treatment of hypertension, angina, and cluster headache prophylaxis.
• Pharmacology: Verapamil is an L-type calcium channel blocker that also has antiarrythmic activity. The R-enantiomer is more effective at reducing blood pressure compared to the S-enantiomer. However, the S-enantiomer is 20 times more potent than the R-enantiomer at prolonging the PR interval in treating arrhythmias.
• Toxicity: LD₅₀=8 mg/kg (i.v. in mice)
• Affected Organisms: Humans and other mammals
• Absorption: 90%
• Half Life: 2.8-7.4 hours
• Protein Binding: 90%
• Elimination: Approximately 70% of an administered dose is excreted as metabolites in the urine and 16% or more in the feces within 5 days. About 3% to 4% is excreted in the urine as unchanged drug.
• References: Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996;36:161-83. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

REFERENCES

• Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996;36:161-83. Pubmed